These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29611459)

  • 1. Physician-Specific Maximum Acceptable Risk in Personalized Medicine: Implications for Medical Decision Making.
    Boeri M; McMichael AJ; Kane JPM; O'Neill FA; Kee F
    Med Decis Making; 2018 Jul; 38(5):593-600. PubMed ID: 29611459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Psychiatrists' decision making and monitoring of antipsychotic prescription for elderly schizophrenia patients].
    Jalenques I; Ortega V; Legrand G; Auclair C
    Encephale; 2016 Apr; 42(2):124-9. PubMed ID: 26796558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of the Risk Functional Form Assumptions on Maximum Acceptable Risk Measures.
    Gonzalez JM; Boeri M
    Patient; 2021 Nov; 14(6):827-836. PubMed ID: 33961275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.
    Levitan B; Markowitz M; Mohamed AF; Johnson FR; Alphs L; Citrome L; Bridges JF
    Psychiatr Serv; 2015 Jul; 66(7):719-26. PubMed ID: 25772762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of Genotype Information on Psychiatrists' Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore.
    McMichael AJ; Boeri M; Rolison JJ; Kane J; O'Neill FA; Scarpa R; Kee F
    Value Health; 2017 Jan; 20(1):126-131. PubMed ID: 28212953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical decision making in antipsychotic drug choice for schizophrenia.
    Hamann J; Langer B; Leucht S; Busch R; Kissling W
    Am J Psychiatry; 2004 Jul; 161(7):1301-4. PubMed ID: 15229068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method for Calculating the Simultaneous Maximum Acceptable Risk Threshold (SMART) from Discrete-Choice Experiment Benefit-Risk Studies.
    Fairchild AO; Reed SD; Gonzalez JM
    Med Decis Making; 2023 Feb; 43(2):227-238. PubMed ID: 36326189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions.
    Montano-Campos JF; Gonzalez JM; Rickert T; Fairchild AO; Levitan B; Reed SD
    MDM Policy Pract; 2023; 8(1):23814683221148715. PubMed ID: 36654678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient participation in antipsychotic drug choice decisions.
    Hamann J; Kruse J; Schmitz FS; Kissling W; Pajonk FG
    Psychiatry Res; 2010 Jun; 178(1):63-7. PubMed ID: 20452053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia.
    Patel MX; Nikolaou V; David AS
    Psychol Med; 2003 Jan; 33(1):83-9. PubMed ID: 12537039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Do Patients Want from Otolaryngologists? A Discrete Choice Experiment.
    Naunheim MR; Rathi VK; Naunheim ML; Alkire BC; Lam AC; Song PC; Shrime MG
    Otolaryngol Head Neck Surg; 2017 Oct; 157(4):618-624. PubMed ID: 28675119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatrists' Attitude and Use of Second-generation Antipsychotics for the Treatment of Schizophrenia in Taiwan.
    Chen CK; Su HH; Sun IW
    East Asian Arch Psychiatry; 2017 Sep; 27(3):91-6. PubMed ID: 28993541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study.
    Takahashi K; Yamazawa R; Suzuki T; Mimura M; Uchida H
    Neuropsychopharmacol Rep; 2020 Sep; 40(3):232-238. PubMed ID: 32489004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey.
    Liu S; Liu J; Si L; Ke X; Liu L; Ren Y; Bao S; Li F; Yu Y; Pan Q; Wei Y; Chen Y
    BMJ Glob Health; 2023 Apr; 8(4):. PubMed ID: 37041021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
    Linley WG; Hughes DA
    Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Empirical Comparison of Discrete Choice Experiment and Best-Worst Scaling to Estimate Stakeholders' Risk Tolerance for Hip Replacement Surgery.
    van Dijk JD; Groothuis-Oudshoorn CG; Marshall DA; IJzerman MJ
    Value Health; 2016 Jun; 19(4):316-22. PubMed ID: 27325322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Heterogeneity in Patients' Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches.
    Boeri M; Saure D; Schacht A; Riedl E; Hauber B
    Pharmacoeconomics; 2020 Jun; 38(6):593-606. PubMed ID: 32128726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment.
    Markowitz MA; Levitan BS; Mohamed AF; Johnson FR; Bridges JF; Alphs L; Citrome L
    Psychiatr Serv; 2014 Sep; 65(9):1133-9. PubMed ID: 24828964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission as perceived by people with schizophrenia, family members and psychiatrists.
    Karow A; Naber D; Lambert M; Moritz S;
    Eur Psychiatry; 2012 Aug; 27(6):426-31. PubMed ID: 21571506
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.